Effect of stopping tyrosine kinase inhibitors during pregnancy on disease status and reproductive outcomes among patients with chronic myeloid leukemia

• Published in: Zhōnghuá xuèyèxué zázhì 2018-07, Vol.39 (7), p.540-545
• Main Authors: Zhao, H F, Zhang, Yanli, Li, Z, Zhou, J, Zu, Y L, Yu, F K, Gui, R R, Wei, X D, Song, Y P
• Format: Article
• Language: Chinese
• Subjects: Adult; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate - therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Pregnancy; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; Young Adult
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2018.07.003

To explore the pregnancy outcome and disease status among patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitor (TKI) when they stopped TKI treatment during pregnancy. The clinical characteristics, reproductive outcomes and disease status of the patients who stopped TKI due to pregnancy between November 2004 to November 2017 were retrospectively collected. A total of 14 CML patients in chronic phase (CML-CP), 12 patients were Sokal-low-risk. The median time of TKI treatment was 46.5 (15-123) months before the drug was stopped. The median age at the time of pregnancy was 29 (24-32) years. The median time of TKI exposure was 4 (0-9) weeks in 12 accidental pregnancies. Outcomes were available for 13 pregnancies, 9 cases (69.2%) delivered healthy babies, 1 case (7.7%) delivered polydactylia malformation baby, 3 cases (23.1%) had spontaneous abortion. The last one was still in pregnancy (no organ malformations were observed in color Doppler ultrasound). At the end of the follow up dat